Ivacaftor potentiation of multiple CFTR channels with gating mutations.

BACKGROUND The investigational CFTR potentiator ivacaftor (VX-770) increased CFTR channel activity and improved lung function in subjects with CF who have the G551D CFTR gating mutation. The aim of this in vitro study was to determine whether ivacaftor potentiates mutant CFTR with gating defects caused by other CFTR gating mutations. METHODS The effects of ivacaftor on CFTR channel open probability and chloride transport were tested in electrophysiological studies using Fischer rat thyroid (FRT) cells expressing different CFTR gating mutations. RESULTS Ivacaftor potentiated multiple mutant CFTR forms with defects in CFTR channel gating. These included the G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P and G1349D CFTR gating mutations. CONCLUSION These in vitro data suggest that ivacaftor has a similar effect on all CFTR forms with gating defects and support investigation of the potential clinical benefit of ivacaftor in CF patients who have CFTR gating mutations beyond G551D.

[1]  R. Boucher.  Cystic fibrosis: a disease of vulnerability to airway surface dehydration. , 2007, Trends in molecular medicine.

[2]  M. Nöthen,et al.  High incidence of the CFTR mutations 3272-26A-->G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A-->G, E588V, and 1671insTATCA). , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  L. Tsui,et al.  Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. , 1991, Genomics.

[4]  M. Welsh,et al.  Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. , 1992, Science.

[5]  R. Ravazzolo,et al.  Antihypertensive 1,4-Dihydropyridines as Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating Defect Caused by Cystic Fibrosis Mutations , 2005, Molecular Pharmacology.

[6]  Nicoletta Pedemonte,et al.  Phenylglycine and Sulfonamide Correctors of Defective ΔF508 and G551D Cystic Fibrosis Transmembrane Conductance Regulator Chloride-Channel Gating , 2005, Molecular Pharmacology.

[7]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[8]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[9]  J. Rommens,et al.  Cystic Fibrosis Mutations Lead to Carboxyl-terminal Fragments That Highlight an Early Biogenesis Step of the Cystic Fibrosis Transmembrane Conductance Regulator* , 2000, The Journal of Biological Chemistry.

[10]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[11]  J. Riordan,et al.  Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel. , 1997, Biochemistry.

[12]  N. Pedemonte,et al.  Mutation-Specific Potency and Efficacy of Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Potentiators , 2009, Journal of Pharmacology and Experimental Therapeutics.

[13]  M. Klein,et al.  Insight in eukaryotic ABC transporter function by mutation analysis , 2006, FEBS letters.

[14]  J. Elborn,et al.  Clinical phenotype of cystic fibrosis patients with the G551D mutation. , 2009, QJM : monthly journal of the Association of Physicians.

[15]  J. Riordan,et al.  Cytoplasmic Loop Three of Cystic Fibrosis Transmembrane Conductance Regulator Contributes to Regulation of Chloride Channel Activity* , 1996, The Journal of Biological Chemistry.

[16]  R. Moss,et al.  Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. , 1999, American journal of physiology. Cell physiology.

[17]  A. Taddei,et al.  Differential Sensitivity of the Cystic Fibrosis (CF)-associated Mutants G551D and G1349D to Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Cl– Channel* , 2006, Journal of Biological Chemistry.

[18]  M. Welsh,et al.  Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties , 1993, Nature.

[19]  B. Kerem,et al.  Consensus on the Use and Interpretation of Cystic Fibrosis Mutation Analysis in Clinical Practice , 2022 .

[20]  M. Welsh,et al.  Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. , 1995, The EMBO journal.

[21]  L. Orozco,et al.  Mild cystic fibrosis disease in three Mexican delta‐F508/G551S compound heterozygous siblings , 1995, Clinical genetics.

[22]  Nikolay V. Dokholyan,et al.  Multiple Membrane-Cytoplasmic Domain Contacts in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mediate Regulation of Channel Gating* , 2008, Journal of Biological Chemistry.

[23]  S. Emerson,et al.  Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study , 2003, The Lancet.

[24]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[25]  Jinglan Zhou,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[26]  O. Moran,et al.  Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains , 2005, Cellular and Molecular Life Sciences CMLS.

[27]  G. Cutting,et al.  Two cystic fibrosis transmembrane conductance regulator mutations have different effects on both pulmonary phenotype and regulation of outwardly rectified chloride currents. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[29]  D. Sheppard,et al.  Gating of the CFTR Cl− channel by ATP‐driven nucleotide‐binding domain dimerisation , 2009, The Journal of physiology.